IO Biotech appoints Dr Peter Hirth as Chairman of the Board

Oct 4, 2016

Copenhagen, Denmark – October 4, 2016: IO Biotech today announced that industry veteran Dr Peter Hirth will succeed Dr Hans Schambye as Chairman of the Board of Directors. IO Biotech develops novel therapeutic immuno-oncology vaccines targeting immune check point inhibitory targets to treat cancer.

Other news

IO Biotech Announces Appointment of Devin Smith as General Counsel

IO Biotech Announces Appointment of Devin Smith as General Counsel

IO Biotech Provides Business Update

IO Biotech Provides Business Update